TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT04595929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy according to indications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Adjuvant chemotherapy according to indications.
Study: NCT02766127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Veritise Flow
Description: Self-adhering composite

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal Dentin Sealant
Description: non-polymerizable, high molecular weight resin sealant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Description: methacrylate-based resin, self-etching adhesive system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flor-Opal® Varnish
Description: fluoride-based varnish
Study: NCT04027959

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
Study: NCT03790696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Training Program
Description: The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training Program
Description: The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears.
Study: NCT00734136

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draws and a hepatectomy specimen
Description: Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw - pre operative standard of care
Description: Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
Study: NCT03941600

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based Exercise Intervention group (CBE)
Description: The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Education Control group (EEG)
Description: The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
Study: NCT04149938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical system 1.8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Study: NCT02178930

Intervention type: OTHER
Group type: OTHER
Intervention: Integrated self management support
Description: The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
Study: NCT03195361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRS - Self Retaining Support system
Study: NCT01810939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patiromer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01384812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dinoprostone
Description: intravenous injection 0.4 μgr/kg/min for 25 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isoton sodium chloride
Description: intravenous injection for 25 min
Study: NCT00697398

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial stimulation
Description: Stimulation to white

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS)
Study: NCT03003377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask supreme
Description: Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
Study: NCT02634801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fumaric Acid Esters
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered orally
Study: NCT03003377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask proseal
Description: Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
Study: NCT03995927

Intervention type: OTHER
Intervention: Data collection and analysis
Description: Only radiation oncology patients data from medical records regarding treatment, demographics and follow-up visits will be collected and logged by investigators.
Study: NCT02634801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC
Study: NCT01366183

Intervention type: PROCEDURE
Intervention: Assessment of Therapy Complications
Description: Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments

Intervention type: DRUG
Intervention: Carboplatin
Description: Undergo chemotherapy

Intervention type: BIOLOGICAL
Intervention: Filgrastim
Description: Undergo chemotherapy

Intervention type: DRUG
Intervention: Paclitaxel
Description: Undergo chemotherapy

Intervention type: OTHER
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01863342

Intervention type: PROCEDURE
Intervention: CSI score < 40

Intervention type: PROCEDURE
Intervention: CSI score ≥ 40
Study: NCT03743727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined therapy LDV and SOF
Description: All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
Study: NCT03629808

Intervention type: PROCEDURE
Intervention: 4-6cm from starting point of gastrectomy to pylorus
Description: The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.

Intervention type: PROCEDURE
Intervention: 2-4cm from starting point of gastrectomy to pylorus
Description: The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
Study: NCT03714776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching solution administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 757456
Description: Administered as SC injection.
Study: NCT03077425

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Per Arm/Group Description, CHWs will provide a pamphlet and dental referral list to participants both groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Per Arm/Group Description, CHWs will a) conduct 6 home visits with mothers/families over a 12 month period along with follow-up phone support, and b) patient navigation support for child to receive 2 dental visits: one by 12 months of age and one by 18 months of age.
Study: NCT00038805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Study: NCT05573178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac ganglion plexus ablation(cardioneuroablation)
Description: Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cardiac ganglion plexus ablation(cardioneuroablation)
Description: Under the guidance of three-dimensional system, the located ganglion plexus was ablated with saline irrigating electrode. The upper limit of power was 40W, the upper limit of temperature was 43 ℃, and the washing rate of saline was 17ml/min. The site of vagal reaction during ablation was defined as the effective ablation site. The surgical end point of denervated interventional therapy is defined as the disappearance of vagal response at the effective ablation site or the ablation of each effective point discharge for at least 30 seconds.
Study: NCT04297696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: A program including warm-up period and neuromuscular exercises is applied progressively in two phases.
Study: NCT02674126

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal sound group
Description: The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
Study: NCT04560868

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control mHealth program
Description: The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental mHealth program
Description: The intervention includes a mHealth intervention that is grounded in best practice recommendations for treatment of nicotine dependence. Experimental participants also receive additional content designed to motivate smoking reduction/quitting and provide skills training.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
Study: NCT03475290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal resources' enhancement: self-efficacy and perceived social support
Description: The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support \& cognitive distortions, social skills \& peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal resources' enhancement: perceived social support and self-efficacy
Description: The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support \& cognitive distortions, social skills \& peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal resources' enhancement: self-efficacy
Description: The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal resources' enhancement: perceived social support
Description: The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support \& cognitive distortions, social skills \& peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
Study: NCT00284011

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SAMe
Description: 800 mg dose daily for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo pills daily for 4 weeks.
Study: NCT00030966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo monthly infusion for up to 116 weeks.
Study: NCT02435563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor 180 mg administrated alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor adjusted dose + ritonavir 100mg
Study: NCT03459508

Intervention type: DIAGNOSTIC_TEST
Intervention: Ophthalmological examination
Description: Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
Study: NCT00878579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDS System
Description: Percutaneous Dynamic Stabilization System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion
Description: Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
Study: NCT01528280

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination against hepatitis A
Description: Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No Intervention
Study: NCT03615820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niosomal PPE oromucoadhesive film
Description: Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Niosomal PPE oromucoadhesive film
Description: Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucoadhesive film
Description: Oromucoadhesive film without PPE control testing which represents Placebo group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oromucoadhesive film
Description: Oromucoadhesive film without PPE control testing which represents Placebo group
Study: NCT02860962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan Hydrobromide
Description: Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan Hydrobromide
Description: Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.